|
DE4310643A1
(de)
*
|
1993-04-01 |
1994-10-06 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
|
US5753230A
(en)
*
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
|
US5945403A
(en)
*
|
1997-05-30 |
1999-08-31 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
|
US5837682A
(en)
|
1996-03-08 |
1998-11-17 |
The Children's Medical Center Corporation |
Angiostatin fragments and method of use
|
|
US6949511B1
(en)
|
1994-04-26 |
2005-09-27 |
The Children's Medical Center Corporation |
Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
|
|
US6660842B1
(en)
|
1994-04-28 |
2003-12-09 |
Tripep Ab |
Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
|
|
EP0719859B1
(en)
*
|
1994-12-20 |
2003-07-02 |
MERCK PATENT GmbH |
Anti-alpha V-integrin monoclonal antibody
|
|
US6440729B1
(en)
|
1995-06-30 |
2002-08-27 |
University Of Kansas Medical Center |
Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
|
|
US6358735B1
(en)
|
1995-06-30 |
2002-03-19 |
University Of Kansas Medical Center |
Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
|
|
CA2227265C
(en)
*
|
1995-08-14 |
2012-01-03 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
|
|
US6100423A
(en)
*
|
1995-08-30 |
2000-08-08 |
G. D. Searle & Co. |
Amino benzenepropanoic acid compounds and derivatives thereof
|
|
ATE203234T1
(de)
|
1995-08-30 |
2001-08-15 |
Searle & Co |
Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten
|
|
ES2206602T3
(es)
*
|
1995-10-23 |
2004-05-16 |
The Children's Medical Center Corporation |
Compuestos y metodos terapeuticos inhibidores de angiogenesis.
|
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
|
US5854205A
(en)
*
|
1995-10-23 |
1998-12-29 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic compositions and methods
|
|
US5854221A
(en)
*
|
1996-12-12 |
1998-12-29 |
The Children's Medical Center Corporation |
Endothelial cell proliferation inhibitor and method of use
|
|
JP4189033B2
(ja)
*
|
1996-08-15 |
2008-12-03 |
ノバルティス アクチエンゲゼルシャフト |
定量的関節炎状態のアッセイ
|
|
GB9708265D0
(en)
*
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
|
EP0846702B1
(en)
*
|
1996-12-09 |
2009-03-11 |
MERCK PATENT GmbH |
Soluble recombinant alphaV beta3 adhesion receptor
|
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
|
US6590079B2
(en)
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
|
ES2234099T3
(es)
|
1997-03-12 |
2005-06-16 |
Smithkline Beecham Corporation |
Anticuerpos monoclanales humanizados anti-alfa beta 3.
|
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
|
US5994388A
(en)
*
|
1997-03-18 |
1999-11-30 |
The Children's Medical Center Corporation |
Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis
|
|
ES2313745T3
(es)
|
1997-03-19 |
2009-03-01 |
Lucid, Inc. |
Cirugia celular que utiliza microscopia confocal.
|
|
PT973550E
(pt)
*
|
1997-04-11 |
2003-01-31 |
Searle & Co |
Anticorpos antagonistas anti-integrina avb3
|
|
AU6954498A
(en)
*
|
1997-04-11 |
1998-11-11 |
G.D. Searle & Co. |
Methods for using antagonistic anti-avb3 integrin antibodies
|
|
US6596276B1
(en)
*
|
1997-09-30 |
2003-07-22 |
Beth Israel Deaconess Medical Center |
Method for inhibiting tumor angiogenesis in a living subject
|
|
US6372719B1
(en)
*
|
1998-03-04 |
2002-04-16 |
Jay Cunningham |
ανβ3 integrin antagonists in combination with chemotherapeutic agents
|
|
US6172256B1
(en)
*
|
1998-03-04 |
2001-01-09 |
G.D. Searle & Co. |
Chiral-β-amino acid compounds and derivatives thereof
|
|
US6524553B2
(en)
|
1998-03-31 |
2003-02-25 |
Bristol-Myers Squibb Pharma Company |
Quinolone vitronectin receptor antagonist pharmaceuticals
|
|
HUP0101468A2
(hu)
|
1998-03-31 |
2001-08-28 |
Du Pont Pharmaceuticals Company |
Angiogenetikus rendellenességek leképzésére alkalmas szerek
|
|
US6548663B1
(en)
|
1998-03-31 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Benzodiazepine vitronectin receptor antagonist pharmaceuticals
|
|
US6537520B1
(en)
|
1998-03-31 |
2003-03-25 |
Bristol-Myers Squibb Pharma Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
|
US6852318B1
(en)
|
1998-05-08 |
2005-02-08 |
The Regents Of The University Of California |
Methods for detecting and inhibiting angiogenesis
|
|
US6759047B1
(en)
|
1998-06-17 |
2004-07-06 |
Beth Israel Deaconess Hospital Corp. |
Anti-angiogenic proteins and methods of use thereof
|
|
US6962974B1
(en)
|
1998-06-17 |
2005-11-08 |
Beth Israel Deaconess Medical Center |
Anti-angiogenic proteins and fragments and methods of use thereof
|
|
US7387779B2
(en)
*
|
1998-06-17 |
2008-06-17 |
Beth Israel Deaconess Medical Center |
Anti-angiogenic proteins and fragments and methods of use thereof
|
|
DK1520588T3
(en)
|
1998-07-13 |
2015-03-23 |
Univ Texas |
Use of antibodies to aminophospholipids for cancer treatment
|
|
RU2167425C2
(ru)
*
|
1998-07-17 |
2001-05-20 |
Малышев Игорь Юрьевич |
Способ определения белков
|
|
US6164281A
(en)
*
|
1998-07-20 |
2000-12-26 |
Zhao; Iris Ginron |
Method of making and/or treating diseases characterized by neovascularization
|
|
WO2000009143A1
(en)
*
|
1998-08-13 |
2000-02-24 |
G.D. Searle & Co. |
Multivalent avb3 and metastasis-associated receptor ligands
|
|
US6979697B1
(en)
*
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
|
US6537554B1
(en)
|
1998-09-10 |
2003-03-25 |
Curagen Corporation |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
|
US6248327B1
(en)
|
1998-09-11 |
2001-06-19 |
Vanderbilt University |
Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
|
|
US7176289B1
(en)
*
|
1998-09-11 |
2007-02-13 |
Vanderbilt University |
Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
|
|
US20030202977A1
(en)
*
|
1998-11-16 |
2003-10-30 |
New York University |
Treatment of osteoarthritis
|
|
US6235877B1
(en)
*
|
1999-08-04 |
2001-05-22 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
|
|
EP1135153B1
(en)
*
|
1998-11-20 |
2005-04-27 |
Genentech, Inc. |
Uses for eph receptor antagonists and agonists to treat vascular disorders
|
|
US6339062B1
(en)
*
|
1998-11-23 |
2002-01-15 |
Inkine Pharmaceutical Company, Inc. |
Retroinverso polypeptides that mimic or inhibit thrombospondin activity
|
|
US6160099A
(en)
*
|
1998-11-24 |
2000-12-12 |
Jonak; Zdenka Ludmila |
Anti-human αv β3 and αv β5 antibodies
|
|
EP1140204A2
(en)
|
1998-12-18 |
2001-10-10 |
Du Pont Pharmaceuticals Company |
Vitronectin receptor antagonist pharmaceuticals
|
|
EP1140864A2
(en)
*
|
1998-12-18 |
2001-10-10 |
Du Pont Pharmaceuticals Company |
Vitronectin receptor antagonist pharmaceuticals
|
|
US6794518B1
(en)
*
|
1998-12-18 |
2004-09-21 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
|
US6511649B1
(en)
|
1998-12-18 |
2003-01-28 |
Thomas D. Harris |
Vitronectin receptor antagonist pharmaceuticals
|
|
US6569402B1
(en)
|
1998-12-18 |
2003-05-27 |
Bristol-Myers Squibb Pharma Company |
Vitronectin receptor antagonist pharmaceuticals
|
|
EP1140194A2
(en)
*
|
1998-12-23 |
2001-10-10 |
G.D. SEARLE & CO. |
Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
|
|
US20050281821A1
(en)
*
|
1999-01-06 |
2005-12-22 |
Flavia Pernasetti |
Method and composition for angiogenesis inhibition
|
|
US6521593B1
(en)
*
|
1999-02-01 |
2003-02-18 |
Childrens Hospital Los Angeles |
Methods for inhibiting brain tumor growth
|
|
EP1156823B1
(en)
*
|
1999-02-12 |
2008-10-29 |
The Scripps Research Institute |
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
|
|
AU4187200A
(en)
*
|
1999-04-01 |
2000-10-23 |
Biostratum, Inc. |
The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
|
|
WO2000067771A1
(en)
*
|
1999-05-06 |
2000-11-16 |
The Burnham Institute |
Antiangiogenic endostatin peptides, endostatin variants and methods of use
|
|
US6890904B1
(en)
*
|
1999-05-25 |
2005-05-10 |
Point Therapeutics, Inc. |
Anti-tumor agents
|
|
US6531580B1
(en)
*
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
|
US6685914B1
(en)
|
1999-09-13 |
2004-02-03 |
Bristol-Myers Squibb Pharma Company |
Macrocyclic chelants for metallopharmaceuticals
|
|
MXPA02003079A
(es)
*
|
1999-09-23 |
2004-04-21 |
Scripps Research Inst |
Metodo y composiciones para inhibir la formacion de adhesion.
|
|
US20080038274A1
(en)
*
|
1999-09-23 |
2008-02-14 |
Foster Keith A |
Inhibition of secretion from non-neuronal cells
|
|
WO2001024823A1
(en)
*
|
1999-10-04 |
2001-04-12 |
Chiron Corporation |
Cd40 antagonist for treating psoriasis
|
|
DK1905457T3
(da)
|
1999-12-22 |
2012-05-29 |
Scripps Research Inst |
Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
|
|
US7740841B1
(en)
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
|
JP4039856B2
(ja)
*
|
2000-02-03 |
2008-01-30 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
インテグリン発現阻害剤
|
|
US7361643B2
(en)
|
2000-02-09 |
2008-04-22 |
University Of Puerto Rico |
Methods for inhibiting angiogenesis
|
|
WO2001058931A1
(en)
*
|
2000-02-11 |
2001-08-16 |
Duke University |
Method of treating disorders of the eye
|
|
US6573096B1
(en)
*
|
2000-04-01 |
2003-06-03 |
The Research Foundation At State University Of New York |
Compositions and methods for inhibition of cancer invasion and angiogenesis
|
|
US6835806B2
(en)
|
2000-04-03 |
2004-12-28 |
Phoenix Pharmaceuticals, Inc. |
Cell growth regulation system
|
|
WO2001077145A2
(en)
|
2000-04-12 |
2001-10-18 |
Amersham Health As |
Integrin binding peptide derivatives
|
|
US10293056B1
(en)
*
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
|
US7163681B2
(en)
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
|
US7288390B2
(en)
*
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
|
US20030104573A1
(en)
*
|
2000-09-11 |
2003-06-05 |
Shimkets Richard A. |
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
|
|
NO20004795D0
(no)
|
2000-09-26 |
2000-09-26 |
Nycomed Imaging As |
Peptidbaserte forbindelser
|
|
AU1182402A
(en)
*
|
2000-10-02 |
2002-04-15 |
Scripps Research Inst |
Methods and compositions for enhancing angiogenesis
|
|
US6632835B2
(en)
|
2001-02-22 |
2003-10-14 |
Nanodesign Inc. |
Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
|
|
DE10109136A1
(de)
*
|
2001-02-26 |
2002-09-12 |
Cytotools Gmbh |
Mittel, die die Apoptose bei an der Wundheilung beteiligten Zellen inhibieren
|
|
JP2004536786A
(ja)
*
|
2001-03-02 |
2004-12-09 |
メディミューン，インコーポレイテッド |
インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法
|
|
EP1381384B1
(en)
|
2001-04-24 |
2011-05-25 |
Merck Patent GmbH |
COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
|
|
SE0101854L
(sv)
*
|
2001-05-28 |
2002-11-29 |
Bioneris Ab |
Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
|
|
EP1414491A4
(en)
*
|
2001-07-09 |
2005-07-06 |
Elan Pharm Inc |
METHOD OF INHIBITING THE TOXICITY OF AMYLOID
|
|
US7829087B2
(en)
*
|
2001-07-09 |
2010-11-09 |
Elan Pharmaceuticals, Inc. |
Methods of treating cognitive impairment
|
|
EP1404371B1
(en)
|
2001-07-10 |
2019-03-13 |
GE Healthcare UK Limited |
Peptide-based compounds for targeting intergin receptors
|
|
WO2003012122A2
(en)
*
|
2001-07-27 |
2003-02-13 |
University Of Kansas Medical Center |
Crystallized structure of type iv collagen nc1 domain hexamer
|
|
ATE296628T1
(de)
*
|
2001-08-01 |
2005-06-15 |
Merck Patent Gmbh |
Integrinhemmer zur behandlung von augenkrankheiten
|
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
|
CA2459584A1
(en)
*
|
2001-09-05 |
2003-03-13 |
Cynthia C. Bamdad |
Compositions and use thereof in the treatment of cancer
|
|
EP1443963B1
(en)
|
2001-10-22 |
2014-05-21 |
The Scripps Research Institute |
Antibody targeting compounds
|
|
EP1474162A1
(en)
*
|
2002-02-14 |
2004-11-10 |
MERCK PATENT GmbH |
Methods and compositions for the treatment of eye diseases
|
|
WO2003068258A1
(en)
*
|
2002-02-15 |
2003-08-21 |
Richard Brunner |
7s immunoglobulin for treatment of choroidal neovascularisation_
|
|
EP1487492A4
(en)
*
|
2002-03-04 |
2008-10-01 |
Medimmune Inc |
PREVENTION OR TREATMENT OF CANCER USING INTEGRIN ALPHAVBETA3 ANTAGONISTS COMBINED WITH OTHER AGENTS
|
|
WO2003075741A2
(en)
*
|
2002-03-04 |
2003-09-18 |
Medimmune, Inc. |
METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
|
|
JP2005535572A
(ja)
*
|
2002-04-12 |
2005-11-24 |
メディミューン，インコーポレーテッド |
組換え抗インターロイキン−９抗体
|
|
PT2269656E
(pt)
|
2002-07-15 |
2014-12-02 |
Univ Texas |
Anticorpos selecionados e peptídeos de duramicina que se ligam a fosfolipídios aniônicos e aminofosfolipídios e seus usos no tratamento de infecções virais e câncer
|
|
EA008683B1
(ru)
*
|
2002-07-23 |
2007-06-29 |
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган |
Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
|
|
GB0217018D0
(en)
*
|
2002-07-23 |
2002-08-28 |
Bioacta Ltd |
Peptide 1
|
|
US8017737B2
(en)
|
2002-11-19 |
2011-09-13 |
Hasan Kulaksiz |
Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
|
|
EP1578254B1
(en)
|
2002-11-19 |
2013-03-06 |
DRG International, Inc. |
Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
|
|
US7411048B2
(en)
|
2002-11-19 |
2008-08-12 |
Drg International, Inc. |
Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
|
|
AU2004207002A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
|
US7335359B2
(en)
*
|
2003-02-06 |
2008-02-26 |
Tripep Ab |
Glycosylated specificity exchangers
|
|
EP1594898A2
(en)
|
2003-02-06 |
2005-11-16 |
Tripep AB |
Glycosylated specificity exchangers
|
|
KR101224235B1
(ko)
*
|
2003-04-11 |
2013-01-25 |
메디뮨 엘엘씨 |
재조합 ｉｌ９ 항체 및 그의 용도
|
|
JP2007523839A
(ja)
*
|
2003-04-18 |
2007-08-23 |
ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア |
血管新生性障害の治療法
|
|
WO2005016966A2
(en)
*
|
2003-05-16 |
2005-02-24 |
Receptor Biologix, Inc. |
Intron fusion proteins, and methods of identifying and using same
|
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
|
US7605235B2
(en)
|
2003-05-30 |
2009-10-20 |
Centocor, Inc. |
Anti-tissue factor antibodies and compositions
|
|
KR20060035608A
(ko)
*
|
2003-05-30 |
2006-04-26 |
센토코 인코포레이티드 |
항 조직 인자 항체로 종양 성장을 저해하는 방법
|
|
US20050170455A1
(en)
*
|
2003-06-20 |
2005-08-04 |
Qun-Yong Zhou |
Novel prokineticin receptor isoforms and methods of use
|
|
JP2007512347A
(ja)
*
|
2003-11-26 |
2007-05-17 |
デューク・ユニバーシティー |
緑内障を予防するかまたは治療する方法
|
|
EP1718283B1
(en)
|
2004-01-22 |
2013-03-06 |
University of Miami |
Topical co-enzyme q10 formulations and methods of use
|
|
US7271245B2
(en)
*
|
2004-02-13 |
2007-09-18 |
The Scripps Research Institute |
Methods and compositions for inhibition of metastasis
|
|
CA2554537A1
(en)
*
|
2004-02-17 |
2005-09-01 |
Cancervax Corporation |
Method and composition for angiogenesis inhibition
|
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
|
US8187595B2
(en)
|
2004-05-07 |
2012-05-29 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
|
|
DE602005020137D1
(de)
*
|
2004-05-07 |
2010-05-06 |
Univ North Carolina |
Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
|
|
JP2008506366A
(ja)
*
|
2004-05-14 |
2008-03-06 |
レセプター バイオロジックス インコーポレイテッド |
細胞表面受容体アイソフォームならびにその同定および使用方法
|
|
US7528106B2
(en)
|
2004-06-04 |
2009-05-05 |
The Scripps Research Institute |
Compositions and methods for treatment of neovascular diseases
|
|
SI1771474T1
(sl)
*
|
2004-07-20 |
2010-06-30 |
Genentech Inc |
Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
|
|
EP1771565B1
(en)
*
|
2004-07-20 |
2012-09-05 |
The Feinstein Institute for Medical Research |
Rage protein derivatives
|
|
WO2006017619A2
(en)
*
|
2004-08-06 |
2006-02-16 |
The Regents Of The University Of California |
Receptor-binding cyclic peptides and methods of use
|
|
CA2577370A1
(en)
*
|
2004-08-16 |
2006-03-02 |
Medimmune, Inc. |
Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
|
|
JP2008518023A
(ja)
|
2004-10-27 |
2008-05-29 |
メディミューン，インコーポレーテッド |
同族抗原に対する親和性を改変することによる抗体特異性の調節
|
|
KR100679100B1
(ko)
*
|
2004-10-29 |
2007-02-06 |
엘지.필립스 엘시디 주식회사 |
수평 전계 인가형 액정 표시 패널 및 그 제조방법
|
|
EP2364995A1
(en)
*
|
2004-12-23 |
2011-09-14 |
Molmed SpA |
Conjugation product
|
|
WO2006111925A2
(en)
*
|
2005-04-18 |
2006-10-26 |
Sloan-Kettering Institute For Cancer Research |
Inhibition of tumorigenesis by inhibition of a6b4 integrin
|
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
|
US20060286148A1
(en)
*
|
2005-05-18 |
2006-12-21 |
Ppd, Inc. |
Method of forming implants
|
|
EP2364998A1
(en)
|
2005-06-16 |
2011-09-14 |
The Feinstein Institute for Medical Research |
Antibodies against HMGB1 and fragments thereof
|
|
RU2291706C1
(ru)
*
|
2005-06-21 |
2007-01-20 |
Автономная некоммерческая организация Научно-технический центр "Фармбиопресс" |
Применение флаволигнанов для подавления избыточной и патологической пролиферации эндотелия сосудов
|
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
US20070048325A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Dennis Van Epps |
Combination therapies for inhibiting integrin-extracellular matrix interactions
|
|
US8158126B2
(en)
*
|
2005-08-25 |
2012-04-17 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Stem cell fusion model of carcinogenesis
|
|
ES2521679T3
(es)
|
2006-01-18 |
2014-11-13 |
Merck Patent Gmbh |
Terapia específica usando ligandos de integrinas para el tratamiento del cáncer
|
|
EP1984391A4
(en)
|
2006-01-19 |
2009-08-12 |
Eyegene Inc |
PEPTIDE-SUBSTANCED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CONNECTED WITH THE VASCULAR SYSTEM
|
|
NZ574093A
(en)
*
|
2006-06-12 |
2011-03-31 |
Symphogen As |
Pan-cell surface receptor- specific therapeutics
|
|
EP2043603A4
(en)
|
2006-07-11 |
2010-10-27 |
Arubor Corp |
PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
|
|
EP2068889B1
(en)
|
2006-08-10 |
2019-10-23 |
Roy C. Levitt |
Anakinra for use in the treatment of bronchiolitis obliterans syndrome
|
|
WO2008045252A2
(en)
|
2006-10-04 |
2008-04-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered integrin binding peptides
|
|
WO2008087025A2
(en)
|
2007-01-18 |
2008-07-24 |
Merck Patent Gmbh |
Specific therapy and medicament using integrin ligands for treating cancer
|
|
EP2025685B1
(en)
*
|
2007-08-15 |
2013-06-19 |
Canadian Blood Services |
Monoclonal antibodies against BETA3 integrins
|
|
RU2010119556A
(ru)
*
|
2007-10-16 |
2011-11-27 |
Симфоген А/С (Dk) |
Композиции, содержащие оптимизированные мультимеры her1 и her3, и способы их применения
|
|
JP5809415B2
(ja)
|
2007-11-09 |
2015-11-10 |
ペレグリン ファーマシューティカルズ，インコーポレーテッド |
抗ｖｅｇｆ抗体の組成物および方法
|
|
RU2372354C1
(ru)
*
|
2008-02-28 |
2009-11-10 |
Сергей Викторович Луценко |
Слитый белок, имеющий активность ингибитора ангиогенеза
|
|
EP2990487A1
(en)
|
2008-05-08 |
2016-03-02 |
Asuragen, INC. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
|
CA2737146A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
|
ES2569373T3
(es)
|
2008-10-31 |
2016-05-10 |
University Of Louisville Research Foundation, Inc. |
Células madre derivadas del epitelio olfativo y procedimientos para su utilización
|
|
CN102265158A
(zh)
|
2008-12-23 |
2011-11-30 |
通用电气健康护理有限公司 |
99mTc肽基化合物作为骨髓成像剂的应用
|
|
EP2395992A2
(en)
|
2009-02-10 |
2011-12-21 |
The Scripps Research Institute |
Chemically programmed vaccination
|
|
NZ597339A
(en)
|
2009-05-25 |
2013-10-25 |
Merck Patent Gmbh |
Continuous administration of cilengitide in cancer treatments
|
|
FR2949782B1
(fr)
*
|
2009-09-04 |
2015-10-16 |
Isp Investments Inc |
Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
|
|
US8778888B2
(en)
*
|
2009-11-06 |
2014-07-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
|
|
JP2013532628A
(ja)
|
2010-07-16 |
2013-08-19 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
乳癌および／または骨転移の処置に用いるためのペプチド
|
|
TR201810294T4
(tr)
|
2011-02-11 |
2018-08-27 |
Merck Patent Gmbh |
Prostat kanseri tedavisi için anti-alfa-v integrin antikoru.
|
|
US8722044B2
(en)
|
2011-03-15 |
2014-05-13 |
Janssen Biotech, Inc. |
Human tissue factor antibody and uses thereof
|
|
RU2531502C2
(ru)
*
|
2011-08-09 |
2014-10-20 |
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) |
Способ повышения ангиогенной активности стромальных клеток жировой ткани
|
|
RU2481115C1
(ru)
*
|
2011-10-13 |
2013-05-10 |
Общество с ограниченной ответственностью Научно-Производственное Объединение "Тюменькриобанк" |
Средство для заживления ран "целльгель", способ его получения и способ лечения ран различной этиологии полученным средством
|
|
US9775803B2
(en)
|
2011-10-19 |
2017-10-03 |
Samsung Electronics Co., Ltd. |
Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
|
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
|
EP2859113A4
(en)
*
|
2012-06-07 |
2016-04-13 |
Univ Nat Cheng Kung |
Modified fibronectin fragments or variants and uses thereof
|
|
MX2015002465A
(es)
|
2012-08-31 |
2015-11-06 |
Univ North Carolina |
Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
|
|
US9587001B2
(en)
|
2012-10-19 |
2017-03-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Conjugated knottin mini-proteins containing non-natural amino acids
|
|
US20150315154A1
(en)
|
2012-12-07 |
2015-11-05 |
Council Of Scientific & Industrial Research |
Histidinylated cationic amphiphiles, process for preparation therof and their liposomal formulation
|
|
ES2872403T3
(es)
|
2013-03-14 |
2021-11-02 |
Childrens Medical Center |
Péptido Psap para el tratamiento de cánceres que expresan CD36
|
|
US20190144547A1
(en)
|
2015-11-23 |
2019-05-16 |
Merck Patent Gmbh |
Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
|
|
US10786471B2
(en)
|
2017-02-06 |
2020-09-29 |
Massachusetts Institute Of Technology |
Methods and products related to glutaminase inhibitors
|
|
KR102630070B1
(ko)
*
|
2017-03-31 |
2024-01-26 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
알파-v 베타-3-양성인 암 줄기 세포(csc)를 표적화하여 사멸시키고 약물 내성 암을 치료하기 위한 조성물 및 방법
|
|
KR102171433B1
(ko)
*
|
2018-05-25 |
2020-11-02 |
고려대학교 산학협력단 |
조직 재생을 위한 Substance P 펩타이드가 고정된 피브린 젤 및 이의 제조방법
|
|
US12383634B2
(en)
|
2019-07-24 |
2025-08-12 |
Korea Basic Science Institute |
Single domain antibody targeting αVβ3 integrin
|
|
US20210032348A1
(en)
*
|
2019-08-02 |
2021-02-04 |
The Regents Of The University Of California |
Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers
|
|
CA3172092A1
(en)
*
|
2020-04-23 |
2021-10-28 |
David Cheresh |
Compositions and methods for treating cancer
|
|
CN116847887A
(zh)
|
2020-08-27 |
2023-10-03 |
伊诺西治疗公司 |
治疗自身免疫性疾病和癌症的方法和组合物
|